Pharmaceutics_R&D
3.9K views | +0 today
Follow
Pharmaceutics_R&D
Pharmaceutical companies R&D specifically in neuroscience, CNS disease, pain and electrophysiology
Your new post is loading...
Your new post is loading...
Scooped by Julien Hering, PhD
Scoop.it!

Boston’s Got Big Mo in Biotech, But SF is Pushing Back

Boston’s Got Big Mo in Biotech, But SF is Pushing Back | Pharmaceutics_R&D | Scoop.it

San Francisco is used to being No. 1 in lots of things. It’s there in technology, and in biotechnology. Every magazine that ever ranked ‘Best Places to Live’ is practically required to put it near the top. Even Bay Area sports teams are riding high, as the Giants won the World Series, the 49ers are heading to the Super Bowl, and Stanford University won the Rose Bowl. (...) - Xconomy, by Luke Timmerman, 1/21/13

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Big Pharma on campus - News-Sentinel.com

Big Pharma on campus - News-Sentinel.com | Pharmaceutics_R&D | Scoop.it

ST. LOUIS — In their quest for the next big drug discovery, pharmaceutical companies are increasingly teaming up with some of the nation's top universities, recruiting campus scientists as partners and offering schools multimillion-dollar deals to work on experimental drugs in development. (...) - by Alan Scher Zagier of The Associated Press, News-Sentinel, January 14, 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

The Biotech Industry is facing a Patent Cliff and True Disruption – Biotech Part 3 of 6

The Biotech Industry is facing a Patent Cliff and True Disruption – Biotech Part 3 of 6 | Pharmaceutics_R&D | Scoop.it

In February of 2011, Pfizer announced the closing of its R&D center in Sandwich, Kent, United Kingdom.  That center of excellence was a core part of the company’s drug development program.  It employed 2,400 people, covered 80 acres and became known as the “the home of Viagra.”  While Viagra was home grown and not venture backed, the closure of the Pfizer campus signaled a paradigm shift migrating big pharma, in-house R&D to satellite / outsourced drug discovery.  Many of these companies are virtual and have a lean management, contractors doing much of the work and VCs playing a critical role forming and managing these companies.  R&D spending for the pharmaceutical industry fell to $61bn in 2011, down from $68bn in 2010, down again from $70bn in 2009 and 2008 annually (...) -  by Andrew Romans, The Founders Club, 19 December 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Roche Bets On Early-Stage Alzheimer’s: Luca Explains

Roche Bets On Early-Stage Alzheimer’s: Luca Explains | Pharmaceutics_R&D | Scoop.it
In recent months, Alzheimer’s compounds have been hot news. Pfizer and Johnson & Johnson had one that flopped. Eli Lilly released mixed study results that generated a mix of hype and hope. And Merck (back stories here, here and here). And Merck is betting on one in a test with patients suffering mild to moderate symptoms. Meanwhile, another big drugmaker, Roche, is chugging along with a few compounds of its own and hopes its focus on early-stage disease will prove correct. We spoke briefly with Luca Santarelli, the head of neuroscience at Roche, about its efforts… (...) - Pharmalot, By Ed Silverman, December 11th, 2012
more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Hervé Gisserot élu Président du Leem

Hervé Gisserot élu Président du Leem | Pharmaceutics_R&D | Scoop.it
MyPharma Editions, 4 décembre 2012
Julien Hering, PhD's insight:

Hervé Gisserot a été élu mardi 4 décembre 2012 par le Conseil d’Administration du Leem (Les Entreprises du Médicament) à la présidence de l’organisation professionnelle. Les résultats de cette élection seront officiellement proclamés à l’Assemblée Générale du 12 décembre 2012. Le nouveau président prendra ses fonctions le 1er janvier 2013. (...)

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Trends and opportunities for pharmaceutical companies: Pharma 2020

Trends and opportunities for pharmaceutical companies: Pharma 2020 | Pharmaceutics_R&D | Scoop.it

Predicting the future trends of the pharmaceutical, biotech and life sciences industry and the decisions pharma companies need to make to capitalise on opportunities. (...) - PwC

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Investment relief for biotech sector

Investment relief for biotech sector | Pharmaceutics_R&D | Scoop.it
Public markets provide cash injection for struggling field.


Robert Forrester gets a little giddy when he talks about the day his company went public. The otherwise understated chief operating officer of Verastem, a small biotechnology company developing drugs to target cancer stem cells, chuckles and bounces in his chair as he recounts key strategic decisions along the way to the company’s initial public offering (IPO) on 26 January, which raised US$55 million. (...) - by Heidi Ledford, Nature, 14 November 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

A CRO Tries To Create Part Of Its Workforce

A CRO Tries To Create Part Of Its Workforce | Pharmaceutics_R&D | Scoop.it

In a bid to handcraft its workforce Parexel International, one of the larger clinical research organizations, recently struck a deal with Salem State University to offer a certificate program in clinical trial management. Although the CRO has developed similar programs abroad over the past decade, this is the first time the effort will take place in the US. The move comes as CRO’s attempt to fine tune their appeal to the pharmaceutical industry amid growing scrutiny of clinical trial conduct and oversight. We spoke with Albert Siu, vp of learning and development at Parexel, about the hopes for the program and how it will work… (...) - By Ed SilvermanPharmalot, November 7th, 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

The changing face of corporate venturing in biotechnology

The changing face of corporate venturing in biotechnology | Pharmaceutics_R&D | Scoop.it
Corporate venture funds are playing an increasingly important role in supporting life science commercialization. 

Corporate venturing—the practice of establishing a unit of a corporation with the mandate to make strategic investments in entrepreneurial ventures—has emerged as one of the most prominent strategies for opening up innovation to external ideas and knowledge in the life sciences. Venture arms of pharmaceutical and large biotech companies leverage capital surplus generated through traditional revenue streams to create options for future product pipelines, enable access to innovative compounds and share the costs of risky early stage development with external partners. (...) - von Krogh G et al.Nature Biotechnology 30, 911–915 (2012)

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Pioneering study will test if trio of Roche, Lilly drugs can prevent Alzheimer's

Pioneering study will test if trio of Roche, Lilly drugs can prevent Alzheimer's | Pharmaceutics_R&D | Scoop.it

Washington University School of Medicine in St. Louis has pieced together a pioneering new study that will help put a new theory on preventing Alzheimer's to a definitive test.  - FierceBiotech | October 10, 2012 | By John Carroll

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

ANTABIO and WiSEED announce the completion of the first successful round of crowdfunding applied to biotech start-up financing - FierceBiotech

ANTABIO and WiSEED announce the completion of the first successful round of crowdfunding applied to biotech start-up financing.

Labège, France, October 1st, 2012. ANTABIO, the biopharmaceutical antibacterial drug discovery company, and WiSEED, the French crowdfunding platform dedicated to innovative & technologic startups, announce the successful completion of their seed round of financing with a profitable exit of the initial small investors, a world premiere in the field of crowdfunding applied to biotech start-up financing.

Read more: ANTABIO and WiSEED announce the completion of the first successful round of crowdfunding applied to biotech start-up financing (...) - FierceBiotech 

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Drug Makers Join Efforts in Research

Ten of the world’s largest pharmaceutical companies said on Wednesday that they would cooperate on research aimed at accelerating drug development, starting with streamlining clinical trials.

Pharmaceutical companies have collaborated before on areas considered not directly competitive, like finding variants in the human genome and biomarkers to predict disease and the effectiveness of drugs. But the people behind the new effort said it would be the largest of its kind. (...) - By Andrew POLLACK, The New  York Times, September 19, 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

UCB inaugure sa nouvelle usine pilote biotechnologique

UCB inaugure sa nouvelle usine pilote biotechnologique | Pharmaceutics_R&D | Scoop.it

UCB, la société bruxelloise focalisée sur les maladies graves du système nerveux central et du système immunitaire, a inauguré sur son site de Braine-L’Alleud en Belgique sa nouvelle usine pilote biotechnologique. Un investissement de plus de EUR 65 millions qui anticipe une demande croissante de médicaments biologiques. (...) myPharma Editions, 14 septembre 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

La collaboration Genfit-Sanofi franchit sa deuxième étape avec succès

La collaboration Genfit-Sanofi franchit sa deuxième étape avec succès | Pharmaceutics_R&D | Scoop.it

Genfit, société biopharmaceutique spécialisée dans le traitement des maladies cardiométaboliques et des désordres associés, a annoncé lundi avoir démontré l’activité de plusieurs séries chimiques sélectionnées dans le cadre de la seconde approche de son programme de recherche avec le groupe pharmaceutique Sanofi. (...) - MyPharma Editions, 22/01/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Indian pharmaceutical industry to grow 19% in 2013 | pharmaphorum

Indian pharmaceutical industry to grow 19% in 2013 | pharmaphorum | Pharmaceutics_R&D | Scoop.it

This is a pharma news story about the Indian pharmaceutical industry which is expected by analysts to grow 19% in 2013. (...) - pharmaphorum, 14th January, 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Teva Enters Up-to-$376M Deal for Xenon Pain Drug

Teva Enters Up-to-$376M Deal for Xenon Pain Drug | Pharmaceutics_R&D | Scoop.it
Generic drug giant seeks to expand branded portfolio of pain, CNS drugs.

Teva. Pharmaceutical Industries will develop and market Xenon Pharmaceuticals’ clinical-stage pain treatment XEN402 worldwide, as the generic drug giant seeks to expand its branded portfolio of drugs for pain and CNS indications. (...) - Genetic Engineering & Biotechnology News, Dec 11, 2012
more...
No comment yet.
Rescooped by Julien Hering, PhD from All about Pharma by Pharmacomptoir
Scoop.it!

Big pharma companies must push for medication adherence

Big pharma companies must push for medication adherence | Pharmaceutics_R&D | Scoop.it

Pharmaceutical companies lose an estimated $188 billion annually in revenues in the U.S. because patients fail to take their prescribed medications, according to a study by consulting firm Capgemini.

 

Even for the countries in Western Europe such as the Netherlands where medication is fully covered, adherence is still a major concern and growing issue.

 

In the U.S. Medicare payment reforms aim to place an emphasis on preventive health measures affecting other sectors in health care, pharmaceutical companies are no longer alone in facing poor medication adherence.

 

The question is are these false promises or actual achievable objectives because of wrong targeting?

 


Via Lionel Reichardt / le Pharmageek, Rémy TESTON, Pharmacomptoir / Corinne Thuderoz
more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Rhenovia dépose deux brevets pour son timbre transdermique électronique MyPharma Editions | L'Info Industrie & Politique de Santé

Rhenovia dépose deux brevets pour son timbre transdermique électronique MyPharma Editions | L'Info Industrie & Politique de Santé | Pharmaceutics_R&D | Scoop.it

Rhenovia Pharma, une société biotechnologique basée à Mulhouse et spécialisée dans la biosimulation appliquée à la recherche de nouveaux médicaments pour le traitement de maladies neurodégénératives, neurologiques et psychiatriques, a annoncé le dépôt de deux brevets pour son produit RHEpatch (TM), un timbre transdermique intelligent pour les personnes atteintes de maladies chroniques. (...) - myPharma, 28/11/2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

PwC sees golden era for pharmas that dump the junk, innovate - FiercePharma

Pharma players that ditch their stale culture can thrive in tough world. 

The future of pharma may look pretty bleak over the next few years. The patent cliff has laid to waste blockbusters while too many drugs that were to replace them have withered on the Phase III trial vine. Productivity is low and pipelines are full of high-risk molecules with small potential markets. Big Pharma is getting the screws put to it by payers and emerging markets may not be the panacea many predict, but things look great. (...) - by Eric Palmer, FiercePharma, November 20, 2012

more...
No comment yet.
Rescooped by Julien Hering, PhD from Biotech, Pharmas and ideas
Scoop.it!

Les entrepreneurs des technologies de la santé créent leur association

Les entrepreneurs des technologies de la santé créent leur association | Pharmaceutics_R&D | Scoop.it
Son grand frère, le syndicat des entreprises du médicament (Leem), et sa sœur, l’association des sociétés de biotechnologie...

Via Bing!, Herve Ansanay
more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Novartis to produce over 14 blockbuster drugs by 2017

Novartis to produce over 14 blockbuster drugs by 2017 | Pharmaceutics_R&D | Scoop.it

Swiss pharmaceutical company, Novartis, has given a positive assessment of the battle it is facing to produce more blockbuster drugs and overcome the so-called “patent cliff”.
Over the past few years, many of Novartis’ key drugs have lost exclusivity in major markets and are coming up against tough generic competition. However, the pharma company has announced it is confident it can retain its success and growth in the future, with over 139 projects currently in clinical development. These projects include more than 73 new molecular entities, spread across a wide area of diseases, including cancer, heart and respiratory treatments. (...) - by Hannah Blake, pharmaphorum, 8th November 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

UCB annonce sa troisième collaboration de recherche avec l’université de Harvard

UCB annonce sa troisième collaboration de recherche avec l’université de Harvard | Pharmaceutics_R&D | Scoop.it

Le groupe biopharmaceutique belge UCB a annoncé le lancement d’un troisième projet de recherche en collaboration avec l’université de Harvard, renforçant ainsi l’alliance de recherche innovante conclue par les deux parties en 2011. Ce nouveau projet sera axé sur le microbiome humain en vue du développement de nouvelles applications immunologiques.
Ce troisième projet de recherche sera dirigé par le Dr Christophe Benoist, diplômé en médecine et en philosophie, le Dr Dennis Kasper, diplômé en médecine, et la Dr Diane Mathis, diplômée en philosophie, tous trois professeurs au département de microbiologie et d’immunologie, division « Immunologie », de la faculté de médecine de Harvard. L’équipe étudiera le microbiome humain de l’intestin, typant de nouvelles espèces en étudiant leur impact sur le système immunitaire afin de mettre au point de nouveaux médicaments qui permettront d’éviter ou de traiter les maladies immunologiques. UCB investira dans le projet jusqu’à 4,5 millions de dollars, répartis sur trois ans. (...) - MyPharma Editions, 12/10/2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

EyeBrain lève 3,3 millions d’euros pour développer sa force commerciale

EyeBrain lève 3,3 millions d’euros pour développer sa force commerciale | Pharmaceutics_R&D | Scoop.it

EyeBrain, société basée à Ivry-sur-Seine et qui développe des marqueurs du fonctionnement cérébral pour les maladies neurologiques et psychiatriques, vient d’annoncer une levée de fonds de 3,3 millions d’euros lors de son deuxième tour de table. EyeBrain prévoit d’utiliser les fonds pour développer sa force commerciale, tout en poursuivant ses efforts de R&D.
Cette augmentation de capital est souscrite par Octalfa, Sudinnova et CM-CIC Capital Innovation, trois nouveaux entrants, qui rejoignent les investisseurs historiques, CapDecisif Management et G1JIDF. Lors du premier tour réalisé en 2009 auprès de ces deux fonds, EyeBrain avait levé 1,2 million d’euros. (...) - MyPharma Editions, 9 octobre 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

New cures sought from old drugs

New cures sought from old drugs | Pharmaceutics_R&D | Scoop.it
Researchers to re-examine compounds shelved by industry.


Progeria is a rare, lethal disease that ages children so rapidly that they seem to be 80 years old when they are just 10. So patients and families celebrated the news last week of the first therapeutic success against the disease — as did advocates of the notion that abandoned drugs can rise again. A clinical trial has shown improved symptoms in children with the disease who used lonafarnib (L. B. Gordon Proc. Natl Acad. Sci. USA http://doi.org/jfz; 2012), a drug developed by Merck in the 1990s that failed against its original target, head and neck cancer. (...) - by Meredith Wadman, Nature News, 3 October, 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Report: Schizophrenia drug sales are shrinking, but growth will return

Report: Schizophrenia drug sales are shrinking, but growth will return | Pharmaceutics_R&D | Scoop.it

The market for schizophrenia drugs will shrink over the next couple of years, Decision Resources finds, but will bounce back after that, thanks to new drugs that can be priced at a premium to older treatments.  - September 20, 2012 | By Tracy StatonFiercePharma

more...
No comment yet.